Expanding role of cytomegalovirus as a human pathogen

Journal of Medical Virology

Volumn 88, Issue 7, 2016, Pages 1103-1112

  Navarro, David ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Critically ill patients; Cytomegalovirus; Glioblastoma multiforme; Host genetics; T cell immunity; Transplant recipients

Indexed keywords

ALEMTUZUMAB; CHEMOKINE RECEPTOR CCR5; CORTICOSTEROID; CYTOMEGALOVIRUS ANTIGEN PP65; DENDRITIC CELL VACCINE; GANCICLOVIR; INTERLEUKIN 10; INTERLEUKIN 16; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VALGANCICLOVIR; ACICLOVIR; ANTIVIRUS AGENT;

ACUTE LUNG INJURY; ADOPTIVE IMMUNOTHERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CRITICALLY ILL PATIENT; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; GASTROINTESTINAL DISEASE; GENE DOSAGE; GLIOBLASTOMA; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOCOMPETENCE; INFECTION PREVENTION; INTENSIVE CARE UNIT; LUNG INJURY; MORBIDITY; MORTALITY; NONHUMAN; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PATHOGENESIS; RECIPIENT; RESPIRATORY FAILURE; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T CELL DEPLETION; TUMOR GROWTH; VIRUS REACTIVATION; VIRUS REPLICATION; COMPLICATION; CYTOMEGALOVIRUS; DRUG EFFECTS; GENETICS; GRAFT RECIPIENT; IMMUNOCOMPROMISED PATIENT; PATHOGENICITY; VIROLOGY;

ACYCLOVIR; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; IMMUNOCOMPROMISED HOST; RISK FACTORS; TRANSPLANT RECIPIENTS;

EID: 84953439099     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24450     Document Type: Article

References (121)

1. Abate D, Saldan A, Fiscon M, Cofano S, Paciolla A, Furian L, Ekser B, Biasolo MA, Cusinato R, Mengoli C, Bonfante L, Rossi B, Rigotti P, Sgarabotto D, Barzon L, Palù G. 2010. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 202:585-594.
2. Baumgarten P, Michaelis M, Rothweiler F, Starzetz T, Rabenau HF, Berger A, Jennewein L, Braczynski AK, Franz K, Seifert V, Steinbach JP, Allwinn R, Mittelbronn M, Cinatl J Jr. 2014. Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico- virological diagnostics. Neuro Oncol 16:1469-1477.
3. Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E, Martín-Peña A, Sanchez B, Martin-Gandul C, Gentil MA, Gomez-Bravo MA, Lage E, Perez-Romero P. 2011. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 91:927-933.
4. Bhattacharjee B, Renzette N, Kowalik TF. 2012. Genetic analysis of cytomegalovirus in malignant gliomas. J Virol 86:6815-6824.
5. Blanquer J, Chilet M, Benet I, Aguilar G, Muñoz-Cobo B, Tellez A, Costa E, Bravo D, Navarro D. 2011. Immunological insights into the pathogenesis of active CMV infection in non-immunosuppressed critically ill patients. J Med Virol 83:1966-1971
6. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L. 2003a. Late cytomegalovirus disease and mortality inrecipients of allogeneic hematopoietic stem cell transplants: Importance of viral load and T-cell immunity. Blood 101:407-414.
7. Boeckh M, Ljungman P. 2009. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113:5711-5719.
8. Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers MED, Stevens-Ayers T, Jerome KR, Leisenring W. 2015. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A randomized trial. Annal Intern Med 162:1-10.
9. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. 2003b. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9:543-558.
10. Bravo D, Clari MA, Aguilar G, Belda J, Giménez E, Carbonell JA, Henao L, Navarro D. 2014a. Looking for biological factors to predict the risk of active cytomegalovirus infection in non-immunosuppressed critically ill patients. J Med Virol 86:827-833.
11. Bravo D, Solano C, Giménez E, Remigia MJ, Corrales I, Amat P, Navarro D. 2014b. Effect of the IL28B Rs 12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Med Virol 86:838-844.
12. Brown RA, Gralewski JH, Razonable RR. 2009. The R753Q polymorphism abrogates toll-like receptor 2 signaling in response to human cytomegalovirus. Clin Infect Dis 49: e96-e99.
13. Calarota SA, Aberle JH, Puchhammer-Stöckl E, Baldanti F. 2015. Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications. J Clin Virol 70:109-119.
14. Cantisán S, Lara R, Montejo M, Redel J, Rodríguez-Benot A, Gutiérrez-Aroca J, González-Padilla M, Bueno L, Rivero A, Solana R, Torre-Cisneros J. 2013. Pretransplant interferon-ã secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant 13:738-745.
15. Cervera C, Balderramo D, Suárez B, Prieto J, Fuster F, Linares L, Fuster J, Moreno A, Lozano F, Navasa M. 2009. Donor mannose-binding lectin gene polymorphisms influence the outcome of liver transplantation. Liver Transpl 15:1217-1224.
16. Cervera C, Lozano F, Saval N, Gimferrer I, Ibañez A, Suárez B, Linares L, Cofán F, Ricart MJ, Esforzado N, Marcos MA, Pumarola T, Oppenheimer F, Campistol JM, Moreno A. 2007. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 83:1493-1500.
17. Chiche L, Forel JM, Roch A, Guervilly C, Pauly V, Allardet-Servent J, Gainnier M, Zandotti C, Papazian L. 2009. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med 37:1850-1857.
18. Chiche L, Forel JM, Thomas G, Farnarier C, Cognet C, Guervilly C, Zandotti C, Vély F, Roch A, Vivier E, Papazian L. 2012. Interferon-γ production by natural killer cells and cytomegalovirus in critically ill patients. Crit Care Med 40:1-8.
19. Chilet M, Aguilar G, Benet I, Belda J, Tormo N, Carbonell JA, Clari MA, Costa E, Navarro D. 2010. Virological and immunological features of active cytomegalovirus infection in nonimmunosuppressed patients in a surgical and trauma intensive care unit. J Med Virol 82:1384-1391.
20. Cinatl J, Scholz M, Kotchetkov R, Vogel JU, Doerr HW. 2004. Molecular mechanisms of the modulatory effects of HCMV infection in tumor cell biology. Trends Mol Med 10:19-23.
21. Clari MA, Aguilar G, Benet I, Belda J, Giménez E, Bravo D, Carbonell JA, Henao L, Navarro D. 2013. Evaluation of cytomegalovirus (CMV)-specific t-cell immunity for the assessment of the risk of active CMV infection in non-immunosuppressed surgical and trauma intensive care unit patients. J Med Virol 85:1802-1810.
22. Coisel Y, Bousbia S, Forel JM, Hraiech S, Lascola B, Roch A, Zandotti C, Million M, Jaber S, Raoult D, Papazian L. 2012. Cytomegalovirus and herpes simplex virus effect on the prognosis of mechanically ventilated patients suspected to have ventilator-associated pneumonia. PLoS ONE 7:e51340.
23. Cook CH, Martin LC, Yenchar JK, Lahm MC, McGuinness B, Davies EA, Ferguson RM. 2003. Occult herpes family viral infections are endemic in critically ill surgical patients. Crit Care Med 31:1923-1929.
24. Cook CH, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak DD. 2006a. Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol 80:9151-9158.
25. Cook CH, Zhang Y, Sedmak DD, Martin LC, Jewell S, Ferguson RM. 2006b. Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice. Crit Care Med 34:842-849.
26. Corrales I, Giménez E, Solano C, Amat P, de la Cámara R, Nieto J, Garcia-Noblejas A, Navarro D. 2015. Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCP-1, IL-10, and TLR9 genes. J Med Virol 87:248-255.
27. de Rooij BJ, van der Beek MT, van Hoek B, Vossen AC, Rogier Ten Hove W, Roos A, Schaapherder AF, Porte RJ, van der Reijden JJ, Coenraad MJ, Hommes DW, Verspaget HW. 2011. Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation. J Hepatol 55:800-807.
28. Domart Y, Trouillet JL, Fagon JY, Chastre J, Brun-Vezinet F, Gibert C. 1990. Incidence and morbidity of cytomegaloviral infection in patients with mediastinitis following cardiac surgery. Chest 97:18-22.
29. Egli A, Humar A, Kumar D. 2012. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: A primer for the clinician. Clin Infect Dis 55:1678-1689.
30. Egli A, Levin A, Santer DM, Joyce M, O'Shea D, Thomas BS, Lisboa LF, Barakat K, Bhat R, Fischer KP, Houghton M, Tyrrell DL, Kumar D, Humar A. 2014. Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. J Infect Dis 210:717-727.
31. Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M, Christoph S, Gromke T, Kordelas L, Ottinger HD, Ross RS, Horn PA, Schnittger S, Beelen DW. 2011. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: Evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118:1402-1142.
32. Fernández-Ruiz M, Corrales I, Arias M, Campistol JM, Giménez E, Crespo J, López- Oliva MO, Beneyto I, Martín-Moreno PL, Llamas-Fuente F, Gutiérrez A, García-Álvarez T, Guerra-Rodríguez R, Calvo N, Fernández-Rodríguez A, Tabernero-Romo JM, Navarro MD, Ramos-Verde A, Aguado JM, Navarro D; OPERA Study Group. 2015. Association between individual and combined SNPs in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant recipients. Am J Transplant 15:1323-1335.
33. Fernández-Ruiz M, Kumar D, Humar A. 2014. Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunology 3:e12.
34. Fishman JA. 2007. Infection in solid-organ transplant recipients. N Engl J Med 357:2601-2614.
35. Florescu DF, Qiu F, Schmidt CM, Kalil AC. 2014. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis 58:785-803.
36. Forel JM, Martin-Loeches I, Luyt CE. 2014. Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: Pro. Intensive Care Med 40:1945-1949.
37. Freeman RB Jr. 2009. The "indirect" effects of cytomegalovirus infection. Am J Transplant 9:2453-2458.
38. Fryer JF, Heath AB, Anderson R, Minor PD; The Collaborative Study Group. 2010. Collaborative study to evaluate the proposed 1st WHO international standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays (WHO/BS/10.2138) www.who.int/iris/handle/10665/70521
39. Gerna G, Lilleri D, Fornara C, Comolli G, Lozza L, Campana C, Pellegrini C, Meloni F, Rampino T. 2006. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 6:2356-2364.
40. Gerna G, Lilleri D, Chiesa A, Zelini P, Furione M, Comolli G, Pellegrini C, Sarchi E, Migotto C, Bonora MR, Meloni F, Arbustini E. 2011. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant 11:2463-2471.
41. Giménez E, Muñoz-Cobo B, Solano C, Amat P, Navarro D. 2014a. Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: Does it have any clinical value? J Clin Microbiol 52:654-656.
42. Giménez E, Solano C, Azanza JR, Amat P, Navarro D. 2014b. Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. Antimicrob Agents Chemother 58:5602-5605.
43. Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, Riddell SR, Boeckh M. 2013. CMV reactivation after allogeneic HCT and relapse risk: Evidence for early protection in acute myeloid leukemia. Blood 122:1316-1322.
44. Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, Fiallos E, James CD, Cobbs CS. 2013. Cidofovir: A novel antitumor agent for glioblastoma. Clin Cancer Res 19:6473-6483.
45. Hayden RT, Preiksaitis J, Tong Y, Pang X, Sun Y, Tang L, Cook L, Pounds S, Fryer J, Caliendo AM. 2015. Commutability of the first world health organization international standard for human cytomegalovirus. J Clin Microbiol 53:3325-3333.
46. Heininger A, Haeberle H, Fischer I, Beck R, Riessen R, Rohde F, Meisner C, Jahn G, Koenigsrainer A, Unertl K, Hamprecht K. 2011. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care 15:R77.
47. Hellstrand K, Martner A, Bergström T. 2013. Valganciclovir in patients with glioblastoma. N Engl J Med 369:2066.
48. Herbein G, Kumar A. 2014. The oncogenic potential of human cytomegalovirus and breast cancer. Front Oncol 4:1-7.
49. Hoffmann TW, Halimi JM, Büchler M, Velge-Roussel F, Goudeau A, Al Najjar A, Boulanger MD, Houssaini TS, Marliere JF, Lebranchu Y, Baron C. 2008. Association between a polymorphism in the IL-12p40 gene and cytomegalovirus reactivation after kidney transplantation. Transplantation 85:1406-1411.
50. Hoffmann TW, Halimi JM, Büchler M, Velge-Roussel F, Goudeau A, Al-Najjar A, Marliere JF, Lebranchu Y, Baron C. 2010. Association between a polymorphism in the human programmed death-1 (PD-1) gene and cytomegalovirus infection after kidney transplantation. J Med Genet 47:54-58.
51. Humblot S, Martin T, Pasquali JL, Korganow AS. 2001. Blood coagulation disorders during primary cytomegalovirus infection. Arch Intern Med 161:2149-2150.
52. Jaber S, Chanques G, Borry J, Souche B, Verdier R, Perrigault PF, Eledjam JJ. 2005. Cytomegalovirus infection in critically ill patients: Associated factors and consequences. Chest 127:233-241.
53. Jackson SE, Mason GM, Wills MR. 2011. Human cytomegalovirus immunity and immune evasion. Virus Res 157:151-160.
54. Kalil AC, Florescu DF. 2009. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppresed patients in the intensive care unit. Crit Care Med 37:2350-2358.
55. Kang SH, Abdel-Massih RC, Brown RA, Dierkhising RA, Kremers WK, Razonable RR. 2012. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis 205:639-646.
56. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC. 2006. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6:2134-2143.
57. Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR. 2007. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 44:1315-1320.
58. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. 2008. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 8:975-983.
59. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A; Transplantation Society International CMV Consensus Group. 2013. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:333-360.
60. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, Venkataraman S, Humar A. 2009. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 9:1214-1222.
61. Landais I, Nelson JA. 2013. Functional genomics approaches to understand cytomegalovirus replication, latency and pathogenesis. Curr Opin Virol 3:408-415.
62. Lau SK, Chen YY, Chen WG, Diamond DJ, Mamelak AN, Zaia JA, Weiss LM. 2005. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol 18:838-843.
63. Lawler SE. 2015 Cytomegalovirus and glioblastoma; controversies and opportunities. J Neurooncol 123:465-471.
64. Lehrer S, Labombardi V, Green S, Pessin-Minsley MS, Germano IM, Rosenzweig KE. 2011a. No circulating cytomegalovirus in five patients with glioblastoma multiforme. Anticancer Res 31:959-960.
65. Ljungman P, Perez-Bercoff L, Jonsson J, Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J, Barkholt L, Larsson K, Winiarski J, Yun Z, Ringdén O. 2006. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91:78-83.
66. Ljungman P, Brand R, Hoek de la Camara R, Cordonnier C, Einsele H, Styczynski J, Ward KN, Cesaro S; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. 2014. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: A study by the European group for blood and marrow transplantation. Clin Infect Dis 59:473-481.
67. Lopez Roa P, Hill JA, Kirby KA, Leisenring WM, Huang ML, Santo TK, Jerome KR, Boeckh M, Limaye AP. 2015. Coreactivation of human herpesvirus 6 and cytomegalovirus is associated with worse clinical outcome in critically ill adults. Crit Care Med 43:1415-1422.
68. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC. 1999. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340:1462-1470.
69. Lúcia M, Crespo E, Melilli E, Cruzado JM, Luque S, Llaudó I, Niubó J, Torras J, Fernandez N, Grinyó JM, Bestard O. 2014. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis 59:1537-1545.
70. Lehrer S, Labombardi V, Green S, Pessin-Minsley MS, Germano IM, Rosenzweig KE. 2011b. No circulating cytomegalovirus in five patients with glioblastoma multiforme. Anticancer Res 31:959-960.
71. Limaye AP, Kirby KA, Rubenfels GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang ML, Santo Hayes TK, Corey L, Boeckh M. 2008. Cytomegalovirus reactivation in critically immunocompetent patients. JAMA 300:413-422.
72. Lisboa LF, Kumar D, Wilson LE, Humar A. 2012. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 93:195-200.
73. Loeffler J, Steffens M, Arlt E-M, Toliat M-R, Mezger M, Suk A, Wienker TF, Hebart H, Nürnberg P, Boeckh M, Ljungman P, Trenschel R, Einsele H. 2006. Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation. J Clin Microbiol 44:1847-1850.
74. Manuel O. 2013. Clinical experience with immune monitoring for cytomegalovirus in solid-organ transplant recipients. Curr Infect Dis Rep 29 [Epub ahead of print].
75. Manuel O, Wójtowicz A, Bibert S, Mueller NJ, van Delden C, Hirsch HH, Steiger J, Stern M, Egli A, Garzoni C, Binet I, Weisser M, Berger C, Cusini A, Meylan P, Pascual M, Bochud PY; Swiss Transplant Cohort Study. 2015. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis 211:906-914.
76. Manuel O, Kralidis G, Mueller NJ, Hirsch HH, Garzoni C, van Delden C, Berger C, Boggian K, Cusini A, Koller MT, Weisser M, Pascual M, Meylan PR; The Swiss Transplant Cohort Study. 2013. Incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 13:2402-2410.
77. Mezger M, Steffens M, Semmler C, Arlt E-M, Zimmer M, Kristjanson G-I, Wienker TF, Toliat MR, Kessler T, Einsele H, Loeffler J. 2008. Investigation of promoter variations in dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) (CD209) and their relevance for human cytomegalovirus reactivation and disease after allogeneic stem-cell transplantation. Clin Microbiol Infect 14:228-234.
78. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH. 2008. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10:10-18.
79. Mitsani D, Nguyen MH, Girnita DM, Spichty K, Kwak EJ, Silveira FP, Toyoda Y, Pilewski JM, Crespo M, Bhama JK, Abdel-Massih R, Zaldonis D, Zeevi A, Clancy CJ. 2011. Polymorphism linked to elevated levels of interferon-gamma is associated with an increased risk of cytomegalovirus disease among Caucasian lung transplant recipients at a single center. J Heart Lung Transplant 30:523-529.
80. Mocarski JE, Shenk T, Pass R. 2007. Cytomegaloviruses, In: Knipe D, Howley P, editors. Fields virology 5th edition. Philadelphia, PA: Lippincott Williams and Wilkins, pp 2702-2772.
81. Mumtaz K, Faisal N, Husain S, Morillo A, Renner EL, Shah PS. 2015. Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: A systematic review and meta-analysis. Am J Transplant 15:472-481.
82. Muñoz-Cobo B, Solano C, Costa E, Bravo D, Clari MÁ, Benet I, Remigia MJ, Montoro J, Navarro D. 2011. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: Implications for designing preemptive antiviral therapy strategies. Biol Blood Marrow Transplant 17:1602-1611.
83. Nebbia G, Mattes FM, Smith C, Hainsworth E, Kopycinski J, Burroughs A, Griffiths PD, Klenerman P, Emery VC. 2008. Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant 8:2590-2599.
84. Nicholson E, Peggs KS. 2015. Cytomegalovirus-specific T-cell therapies: Current status and future prospects. Immunotherapy 7:135-146.
85. Ong DS, Spitoni C, Klein Klouwenberg PM, Verduyn Lunel FM, Frencken JF, Schultz MJ, van der Poll T, Kesecioglu J, Bonten MJ, Cremer OL. 2015. Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome. Intensive Care Med. September 28 [Published ahead of print].
86. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. 2007. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem celltransplantation for hematological malignancies. Bone Marrow Transplant 40:125-136.
87. Papazian L, Fraisse A, Garbe L, Zandotti C, Thomas P, Saux P, Pierrin G, Gouin F. 1996. Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology 84:280-287.
88. Papazian L, Hraiech S, Lehingue S, Roch A, Chiche L, Wiramus S, Forel JM. 2015. Cytomegalovirus reactivation in ICU patients. Intensive Care Med 42:28-37.
89. Pérez Romero P, Blanco P, Giménez E, Solano C, Navarro D. 2015. An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. Future Virol 10:113-134.
90. Poole E, Sinclair J. 2015. Sleepless latency of human cytomegalovirus. Med Microbiol Immunol 204:421-429.
91. Popovic M, Smiljanic K, Dobutivic B, Syrovets T, Simmet T, Isenovic ER. 2012. Human cytomegalovirus and atherothrombosis. J Thromb Thrombolysis 33:160-172.
92. Price RL, Song J, Bingmer K, Kim TH, Yi J-Y, Nowicki MO, Mo X, Hollon T, Murnan E, Alvarez-Breckenridge C, Fernandez S, Kaur B, Rivera A, Oglesbee M, Cook C, Chiocca EA, Kwon C-H. 2013. Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res 73:3441-3450.
93. Prins RM, Cloughesy TF, Liau LM. 2008. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 359:539-541.
94. Prösch S, Wendt CE, Reinke P, Priemer C, Oppert M, Krüger DH, Volk HD, Döcke WD. 2000. A novel link between stress and human cytomegalovirus (HCMV) infection: Sympathetic hyperactivity stimulates HCMV activation. Virology 272:357-365.
95. Rahbar A, Orrego A, Peredo I, Dzabic M, Wolmer-Solberg N, Strååt K, Stragliotto G, Söderberg-Nauclér C. 2013. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J Clin Virol 57:36-42.
96. Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kalejta RF. 2012. Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples. J Virol 86:854-864.
97. Razonable RR, Hayden RT. 2013. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev 26:703-727.
98. Razonable RR, Humar A; The AST Infectious Diseases Community of Practice. 2013. Cytomegalovirus in solid organ transplantation. Am J Transplant 13:93-106.
99. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. 2008. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8:69-77.
100. Reischig T, Hribova P, Jindra P, Hes O, Bouda M, Treska V, Viklicky O. 2012. Long-term outcomes of preemptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol 23:1588-1597.
101. Renzette N, Pokalyuk C, Gibson L, Bhattacharjee B, Schleiss MR, Hamprecht K, Yamamoto AY, Mussi-Pinhata MM, Britt WJ, Jensen JD, Kowalik TF. 2015. Limits and patterns of cytomegalovirus genomic diversity in humans. Proc Natl Acad Sci USA 112:E4120-E4128.
102. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. 1992. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238-241.
103. Sabatier J, Uro-Coste E, Pommepuy I, Labrousse F, Allart S, Trémoulet M, Delisle MB, Brousset P. 2005. Detection of human cytomegalovirus genome and gene products in central nervous system tumours. Br J Cancer 92:747-750.
104. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. 2008. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 116:79-86.
105. Schuessler A, Walker DG, Khanna R. 2014. Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme. Front Oncol 4:275.
106. Sester M, Sester U, Gärtner B, Heine G, Girndt M, Mueller-Lantzsch N, Meyerhans A, Köhler H. 2001. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:1287-1294.
107. Söderberg-Nauclér, C. 2008. HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 41:218-223.
108. Söderberg-Nauclér C. 2014. Treatment of cytomegalovirus infections beyond acute disease to improve human health. Expert Rev Anti Infect Ther 12:211-222.
109. Söderberg-Nauclér C, Johnsen JI. 2015. Cytomegalovirus in human brain tumors: Role in pathogenesis and potential treatment options. World J Exp Med 5:1-10.
110. Söderberg-Nauclér C, Rahbar A, Stragliotto G. 2013. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med 369:985-986.
111. Solano C, de la Cámara R, Vázquez L, López J, Giménez E, Navarro D. 2015. Cytomegalovirus infection management in allogeneic stem cell transplant recipients: A national survey in Spain. J Clin Microbiol 53:2741-2744.
112. Solano C, Benet I, Remigia MJ, de la Cámara R, Muñoz-Cobo B, Costa E, Clari MÁ, Bravo D, Amat P, Navarro D. 2011. Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: A pilot experience. Transplantation 92:e17-e20.
113. Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, Bjurman B, Tammik C, Skarman P, Peredo I, Söderberg-Nauclér C. 2013. Effects of valganciclovir as an add- on therapy in patients with cytomegalovirus-positive glioblastoma: A randomized, double-blind, hypothesis-generating study. Int J Cancer 133:1204-1213.
114. Taher C, de Boniface J, Mohammad AA, Religa P, Hartman J, Yaiw KC, Frisell J, Rahbar A, Söderberg-Naucler C. 2013. High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS ONE 8:e56795.
115. Taher C, Frisk G, Fuentes S, Religa P, Costa H, Assinger A, Vetvik KK, Bukholm IR, Yaiw KC, Smedby KE, Bäcklund M, Söderberg-Naucler C, Rahbar A. 2014. High prevalence of human cytomegalovirus in brain metastases of patients with primary breast and colorectal cancers. Transl Oncol 7:732-740.
116. Tang KW, Hellstrand K, Larsson E. 2015. Absence of cytomegalovirus in high-coverage DNA sequencing of human glioblastoma multiforme. Int J Cancer 136:977-981.
117. von Muller L, Klemm A, Durmus N, Weiss M, Suger-Wiedeck H, Schneider M, Hampl W, Mertens T. 2007. Cellular immunity and active cytomegalovirus infection in patients with septic shock. J Infect Dis 196:1288-1295.
118. Weller M, Soffietti R, Brada M. 2014. The legend of cytomegalovirus and glioblastoma lives on. Neuro Oncol 16:166.
119. Wick W, Wick A, Platten M. 2014. Good maths is needed to understand CMV data in glioblastoma. Int J Cancer 134:2991-2992.
120. Wick W, Platten M. 2014. CMV infection and glioma, a highly controversial concept struggling in the clinical arena. Neuro Oncol 16:332-333.
121. Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M; VIPP Study Group. 2012. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 93:61-68.